Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Rangering i aksjer #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Aksjekurs
$0.00047446
Markedsverdi
$82.80
Endring (1 dag)
0.00%
Endring (1 år)
-98.16%
Land
FR
Handel Neovacs S.A. (ALNEV)

Kategori

Inntekter for Neovacs S.A. (ALNEV)
Inntekter i Dec 2024 TTM: $-35.33M
Ifølge Neovacs S.A. sine nyeste økonomiske rapporter er selskapets nåværende resultat $-35.33M. I 2023 hadde selskapet et resultat på $-10.63M, en nedgang sammenlignet med resultatet i 2022, som var $-4.66M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Neovacs S.A. fra 2007 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $-35.33M 0.00%
2024 $-35.33M 232.17%
2023 $-10.63M 128.13%
2022 $-4.66M -67.15%
2021 $-14.19M 74.31%
2020 $-8.14M -22.00%
2019 $-10.44M -33.00%
2018 $-15.58M -31.17%
2017 $-22.63M 24.13%
2016 $-18.23M 131.65%
2015 $-7.87M -33.75%
2014 $-11.88M 7.75%
2013 $-11.03M 0.62%
2012 $-10.96M -12.83%
2011 $-12.57M -8.71%
2010 $-13.77M 14.01%
2009 $-12.08M 72.06%
2008 $-7.02M -9.80%
2007 $-7.78M 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$20.51B -58,146.44%
DK
$4.64B -13,244.00%
US
$5.23B -14,907.10%
US
$2.14B -6,151.40%
BE
$1.45B -4,207.73%
NL